Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID REVIVE: Vidofludimus Calcium for Post COVID Syndrome
2024-511628-16-00Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vidofludimus calcium in post-COVID syndrome (3 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Change in physical function (SF-36 Physical Function subscale) from baseline to Day 56. Started May 2024; status: completed.
02
Drugs
vidofludimus calcium
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2024-511628-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511628-16-00.